Interesting to see the CEO for Janssen's venture 'Centyrex' has moved on in the last few months, to now be "Head of Biologics' at Amgen.
This would have to be considered a step up from his role as venture leader at Janssen.
I suspect Hayes was the one who saw the potential in PYC's science.
Here is his Linkedin page .
janssen presentation on centyrins, page-31
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
12.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $559.9M | |||
| Open | High | Low | Value | Volume |
| 12.5¢ | 12.5¢ | 12.0¢ | $185.3K | 1.515M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 166662 | 12.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 12.5¢ | 39575 | 3 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| PYC (ASX) Chart |